Lipoxygenase inhibitor ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
160先天性魚鱗癬1

160. 先天性魚鱗癬


臨床試験数 : 42 薬物数 : 71 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 112
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-015895-87-NL
(EUCTR)
23/12/200901/10/2009Application of zileuton (Zyflo CR) in patients with Sjögren Larsson Syndrome - Zileuton in Sjögren Larsson SyndromeApplication of zileuton (Zyflo CR) in patients with Sjögren Larsson Syndrome - Zileuton in Sjögren Larsson Syndrome Sjögren Larsson syndrome (SLS) is an autosomal recessive inherited neurometabolic disorder which is characterized by a clinical triad of congenital ichthyosis, spastic di- or tetraplegia and mental retardation. A disturbance of lipid metabolism due to deficiency of the microsomal fatty aldehyde dehydrogenase (FALDH) underlies SLS.Trade Name: Zyflo CR
Product Name: zileuton
INN or Proposed INN: ZILEUTON
Other descriptive name: lipoxygenase inhibitor
UMC St RadboudNULLNot RecruitingFemale: yes
Male: yes
20Phase 3Netherlands